home / stock / rcus / rcus message board
Subject | By | Source | When |
---|---|---|---|
Biotechs are starting to react to news...finally. | conix | investorshub | 04/05/2022 3:26:51 PM |
The stock didn't react as well as expected | dinogreeves | investorshub | 05/27/2020 12:46:59 PM |
Also in the DEF 14.....didnt see any information | lovetc | investorshub | 04/22/2020 2:48:12 AM |
shorted some and bought some put at $31 | lovetc | investorshub | 04/22/2020 2:46:30 AM |
RCUS will likely hit 40 this week and | dinogreeves | investorshub | 04/21/2020 1:25:35 AM |
Bought another 1000 shares on that dip, going | dinogreeves | investorshub | 04/20/2020 10:14:42 PM |
Possible huge asset buy, or outright buyout coming | dinogreeves | investorshub | 04/20/2020 9:11:15 PM |
RCUS getting ready to pop to 33-35 dollars. | dinogreeves | investorshub | 04/20/2020 5:47:24 PM |
This is my letter to the shorts with | dinogreeves | investorshub | 04/18/2020 9:04:27 PM |
If this happens the stock will shoot up | dinogreeves | investorshub | 04/18/2020 3:47:56 PM |
News could come from GI*LD that there is | dinogreeves | investorshub | 04/18/2020 3:24:15 PM |
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...
2024-06-04 14:00:07 ET Peter Lawson from Barclays issued a price target of $35.00 for RCUS on 2024-06-04 09:49:00. The adjusted price target was set to $35.00. At the time of the announcement, RCUS was trading at $16.15. The overall price target consensus is at $42.00 wi...